Preventing low platelets during cervical cancer treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Injuries & trauma, Women’s health & pregnancy clinical trials.
This trial tests a pill called herombopag to prevent low platelets caused by chemo and radiation for cervical cancer. The goal is to see if it can help keep your platelet levels safe so you can complete your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have cervical cancer (confirmed by a biopsy or cell test).
- You are 18 years or older.
- You are in good enough health to be up and around (ECOG 0-1).
- Your cancer is stage IB3 to IVA (a specific range of stages).
- Your platelet count dropped during your last chemo (below 50, or below 75 with bleeding risk factors).
- You are not pregnant, breastfeeding, and will use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This trial tests a drug called Hetrombopag to see if it can prevent low platelet counts in people with advanced lung cancer who are receiving certain types of chemotherapy. The goal is to help keep platelet levels safe so you can continue your cancer treatment without delays or dose reductions.
This trial tests if Hetrombopag can prevent low blood platelets caused by gemcitabine and cisplatin chemotherapy for nasopharyngeal carcinoma. It may help patients who had low platelets in a previous chemo cycle.
Hear when a new Thrombopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.